期刊文献+

包裹钆对比剂的PLGA微球研究初步 被引量:2

Studies on Microparticles Enwrapping Gadolinium-based Contrast Agents
下载PDF
导出
摘要 目的:制备包裹钆对比剂的PLGA微球,并评价PLGA微球在磁共振成像中的肾靶向增强效果。方法:Gd-DTPA作为内水相,溶入了PLGA的二氯甲烷有机溶剂作为油相,PVA-0486的水溶液作为外水相,采用复乳法制备包裹钆对比剂的PLGA微球;通过激光粒度分析仪测量微球平均粒径,用等离子体原子发射光谱仪测量微球载药量,并用磁共振成像仪观察微球的肾靶向增强效果。结果:PLGA浓度越大,PVA的浓度越小,合成的PLGA微球的平均粒径越大;PLGA微球对小鼠肾脏有明显的靶向增强作用。结论:包裹钆对比剂的PLGA微球有望成为一种能临床应用于磁共振成像的肾靶向对比剂。 Objective:To prepare of PLGA microparticles enwrapping Gadolinium-based contrast agents,and evaluate of the renal-targeting enhancement effect of these PLGA microparticles in the MRI imaging.Methods:PLGA microparticles enwrapping Gadolinium-based contrast agents were prepared by double emulsion solvent evaporation technique: Gd-DTPA solution as the inner water phase,methylene dichloride orgamic solvent containing PLGA as the oil phase,and PVA-0486 solution as the external water phase.The average diameter of these PLGA microparticles was scaled by Laser particle sizer,the drug loading was scaled by ICP-AES and the image enhancement was testified by MRI instrument.Results:The average diameter of the synthesized PLGA microparticles will become bigger while the concentration of PLGA increases or the concentration of PVA decreases;PLGA microparticles obviously enhance the renal of the mouse in the MRI imaging.Conclusions:PLGA microparticles enwrapping Gadolinium-based contrast agents may be used as a kind of renal-targeting MRI contrast agents in clinic.
出处 《中国医学物理学杂志》 CSCD 2010年第6期2307-2308,2320,共3页 Chinese Journal of Medical Physics
关键词 磁共振成像 钆对比剂 复乳法 PLGA微球 MRI imaging gadolinium-based contrast agents double emulsion method PLGA microparticles
  • 相关文献

参考文献10

  • 1周高峰,王小宜,彭仁罗,王润文,廖伟华,于冀江,李季龙.磁共振成像钆对比剂不良反应的临床观察[J].中国医学影像技术,2002,18(4):388-389. 被引量:23
  • 2韦金喜.钆对比剂的不良反应,36例病例回顾.国外医学:临床放射学分册,1997,3:184-185.
  • 3蔡晓辉,陈宝安.抗肿瘤纳米药物载体的研究进展[J].临床肿瘤学杂志,2010,15(1):90-94. 被引量:5
  • 4Stassen S, Nihant N, Martin V, etal. Microeneapsulation by coacervat ion of poly(lactide-co-glycolide) :I Physicochemlcal characteristics of the phase separation process [J]. Polymer, 1994, 35(4):777-785.
  • 5Dubey RR,Parikh RH. Studies of PLGA microsperes[J]. Pharm Technol Eur, 2004, 16(5):23-29.
  • 6Lemoine D , Preat V, etal.Polymeric nanoparticles as delivery system for influenza virus glycoprotelns [J]. Journal of Controlled Release, 1998,54(1):15 - 27.
  • 7EI-Baseir MM,Phipps MA,Kellaway IW. Preparation and subsequent degradation of poly(L-lactic acid) mlcrosphere suitable for aerosolisation: A physico-chemincal study[J]. Int J Pharm,1997,151:145-153.
  • 8Yilmaz Capan,Byung H.Woo,etal. Influence of formulation parameters on the characteristics of poly (D,L-latide-co-glycolide) microspheres containing poly (L- lysine) complexed plasmid DNA [J]. Control Release. 1999,60(2):279-286.
  • 9尹婕,邓盛齐.肾靶向给药系统的研究进展[J].国外医药(抗生素分册),2005,26(4):145-150. 被引量:2
  • 10吴传斌,魏树礼,卢炜,赵延乐,高文伟.磁性微球的磁响应性及狗肾动脉栓塞实验研究[J].药学学报,1994,29(4):311-315. 被引量:12

二级参考文献62

共引文献38

同被引文献20

  • 1孙建永,赵立,曲楠,孙震鹏,陈立军.纳米-高频脉冲光技术靶向治疗肾癌的实验研究[J].军事医学科学院院刊,2007,31(2):130-132. 被引量:1
  • 2姚静,周建平,平其能.川陈皮素纳米乳的理化性质及其在小鼠体内的分布[J].药学学报,2007,42(6):663-668. 被引量:13
  • 3Alexander AL, McCreery TT, Barrette TR, et al. Microbubbles as novel pressure-sensitive MR contrast agents. Magn eeson Med, 1996,35(6):801 -806.
  • 4Cheung JS, Chow AM, Guo H, et al. Microbubbles as a novel contrast agent for brain MRI. Neuroimage, 2009, 46 (3) : 658- 664.
  • 5Faranesh AZ, Nastley MT, Perez de la Cruz C, et al. In vitro re tease of vascular endothelial growth factor from gadolinium-doped biodegradable microspheres. Magn Reson Med, 2004, 51 (6) : 1265-1271.
  • 6Doiron AL, Chu K, Ali A, et al. Preparation and initial charac terization of biodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI. Proc Natl Acad Sci U S A, 2008, 105(45) :17232-17237.
  • 7Doiron AL, Homan KA, Emelianov S, et al. Poly (lactic-co-gly colic) acid as a carrier for imaging contrast agents. Pharm Res, 2009,26 (3) : 674-682.
  • 8Ao M, Wang Z, Ran H, et al. Gd DTPA-loaded PLGA microbubbles as both ultrasound contrast agent and MRI contrast agent--a feasibility research. J Biomed Mater Res B Appl Bio- mater, 2010,93(2) :55]-556.
  • 9Tilcock C, Unger E, Cullis P, et al. Liposomal Gd-DTPA: Preparation and characterization of relaxivity. Radiology, 1989, 171(1):77- 80.
  • 10Ratzinger G, Agrawal P, Korner W, et al. Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents. Biomaterials, 2010, 31 (33): 8716-8723.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部